Thor Equities has created Thor Sciences, a division specializing in the life sciences sector.
It comes on the heels of Thor’s $152 million acquisition of The Center of Excellence, a 784,000-square-foot campus that spans 48 acres located in Bridgewater, New Jersey. Comprised of laboratory, research and development, and office buildings, the complex features life science companies specializing in pharmaceuticals and health services including anchor tenants Nestlé Health Science, Ashland, and Amneal Pharmaceuticals. Additional tenants include Insmed, Avantor, Nevakar, Solaris Pharma, Clinical Genomics, Matinas BioPharma, Vertice Pharma, 3D Biotek, Unionmed Tech and GSG Scientific. Expansion plans for The Center of Excellence are expected to be in excess of tens of millions of dollars.
“We are pleased to announce the launch of Thor Sciences as well as the acquisition of The Center of Excellence,” said Joseph Sitt, Thor’s chairman and CEO. “We have been an early advocate for the sector, having previously acquired assets in Berkeley and Boston, and are now ready to advance our global platform with the appointment of life sciences expert and new senior vice president, Bill Hunter. Bringing over 20 years of experience to Thor, Bill played an instrumental role in the acquisition of our new aforementioned trophy asset and we are thrilled to welcome him to the Thor team.”
